{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:09:35Z","timestamp":1794575375209,"version":"4.9.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI12C1625"],"award-info":[{"award-number":["HI12C1625"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.biopha.2023.115345","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T03:40:56Z","timestamp":1693453256000},"page":"115345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NF\u03baB signaling"],"prefix":"10.1016","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1564-383X","authenticated-orcid":false,"given":"Seung-Ho","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Kyoung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Ram","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Il-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Hyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Jung","family":"Goo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5073-6129","authenticated-orcid":false,"given":"Mi-Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115345_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of nonalcoholic steatohepatitis: an overview","volume":"4","author":"Parthasarathy","year":"2020","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.biopha.2023.115345_bib2","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.2147\/DDDT.S315724","article-title":"Non-Alcoholic Steatohepatitis (NASH) - a review of a crowded clinical landscape, driven by a complex disease","volume":"15","author":"Fraile","year":"2021","journal-title":"Drug Des., Dev. Ther."},{"key":"10.1016\/j.biopha.2023.115345_bib3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2023.115345_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.105889","article-title":"A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial","volume":"88","author":"Pedrosa","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.biopha.2023.115345_bib5","first-page":"S76","article-title":"GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity","volume":"153 Suppl","author":"Overton","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115345_bib6","article-title":"GPR119: a promising target for nonalcoholic fatty liver disease","volume":"30","author":"Yang","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2023.115345_bib7","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1210\/me.2013-1029","article-title":"Stimulation of proglucagon gene expression by human GPR119 in enteroendocrine L-cell line GLUTag","volume":"27","author":"Chepurny","year":"2013","journal-title":"Mol. Endocrinol. (Baltim., Md. )"},{"key":"10.1016\/j.biopha.2023.115345_bib8","article-title":"A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression.","volume":"144","author":"Kim","year":"2021","journal-title":"Biomed. Pharmacother. = Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2023.115345_bib9","unstructured":"J.W.Y. Keon Wook Kang, Kyeong Lee, Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient, US patent. US 9,895,370 B2, 2018."},{"key":"10.1016\/j.biopha.2023.115345_bib10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/dom.13062","article-title":"Therapeutic application of GPR119 ligands in metabolic disorders","volume":"20","author":"Yang","year":"2018","journal-title":"Diabetes, Obes. Metab."},{"key":"10.1016\/j.biopha.2023.115345_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejphar.2017.02.043","article-title":"APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL\/6 mice","volume":"801","author":"Bahirat","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115345_bib12","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbrc.2017.12.004","article-title":"Co-administration of APD668, a G protein-coupled receptor 119 agonist and linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in mice fed on a high trans-fat diet","volume":"495","author":"Bahirat","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2023.115345_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00795-018-0200-4","article-title":"Combination of APD668, a G protein-coupled receptor 119 agonist with linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in a murine model of non-alcoholic steatohepatitis with diabetes","volume":"52","author":"Bahirat","year":"2019","journal-title":"Med. Mol. Morphol."},{"key":"10.1016\/j.biopha.2023.115345_bib14","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1016\/j.bmcl.2011.04.029","article-title":"Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes","volume":"21","author":"Kim","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2023.115345_bib15","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet (Lond., Engl. )"},{"key":"10.1016\/j.biopha.2023.115345_bib16","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-\u03b1 and -\u03b4, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2023.115345_bib17","doi-asserted-by":"crossref","first-page":"G483","DOI":"10.1152\/ajpgi.00079.2013","article-title":"Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment","volume":"305","author":"Clapper","year":"2013","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.biopha.2023.115345_bib18","doi-asserted-by":"crossref","first-page":"12466","DOI":"10.1038\/srep12466","article-title":"Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis","volume":"5","author":"Saito","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.115345_bib19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.4254\/wjh.v8.i16.673","article-title":"Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy","volume":"8","author":"Kristiansen","year":"2016","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.biopha.2023.115345_bib20","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatol. (Baltim., Md. )"},{"key":"10.1016\/j.biopha.2023.115345_bib21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/lipd.12121","article-title":"Molecular Characterization of Microvesicular and Macrovesicular Steatosis Shows Widespread Differences in Metabolic Pathways","volume":"54","author":"Kristiansen","year":"2019","journal-title":"Lipids"},{"key":"10.1016\/j.biopha.2023.115345_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejphar.2015.11.029","article-title":"Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes","volume":"771","author":"Kim","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.115345_bib23","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.drudis.2017.06.007","article-title":"Mouse models of nonalcoholic steatohepatitis in preclinical drug development","volume":"22","author":"Hansen","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2023.115345_bib24","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep4.1368","article-title":"Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents","volume":"3","author":"Hernandez","year":"2019","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.biopha.2023.115345_bib25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","article-title":"Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis","volume":"24","author":"T\u00f8lb\u00f8l","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2023.115345_bib26","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/ATVBAHA.121.316311","article-title":"GLP-1 (Glucagon-Like Peptide-1) is physiologically relevant for chylomicron secretion beyond its known pharmacological role","volume":"41","author":"Nahmias","year":"2021","journal-title":"Arterioscler., Thromb., Vasc. Biol."},{"key":"10.1016\/j.biopha.2023.115345_bib27","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Investig."},{"issue":"1997","key":"10.1016\/j.biopha.2023.115345_bib28","first-page":"5450","article-title":"Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription","volume":"159","author":"Parry","year":"1950","journal-title":"J. Immunol. (Baltim., Md"},{"key":"10.1016\/j.biopha.2023.115345_bib29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cmet.2011.03.009","article-title":"AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice","volume":"13","author":"Li","year":"2011","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2023.115345_bib30","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2010.09.032","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase","volume":"54","author":"Ben-Shlomo","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2023.115345_bib31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4093\/dmj.2021.0056","article-title":"DA-1241, a Novel GPR119 Agonist, Improves Hyperglycaemia by Inhibiting Hepatic Gluconeogenesis and Enhancing Insulin Secretion in Diabetic Mice","volume":"46","author":"Kim","year":"2022","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.biopha.2023.115345_bib32","article-title":"Autophagy Dysregulation in Metabolic Associated Fatty Liver Disease: A New Therapeutic Target","volume":"23","author":"Chen","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115345_bib33","unstructured":"M.-K.K.Hansu Park, Bo. Ram Lee, Seung Ho Lee, Yu. Na Chae, A novel GPR119 agonist, DA-1241 improves hepatic inflammation and fibrosis in Ob-NASH mice., in: 80th Scientific Sessions of American Diabetes Association, Jun 12\u201316, 2020: p. Presentation No. 217-LB."},{"key":"10.1016\/j.biopha.2023.115345_bib34","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/cts.13235","article-title":"Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH","volume":"15","author":"M\u00f8llerh\u00f8j","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.biopha.2023.115345_bib35","article-title":"Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol","volume":"14","author":"Yang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.115345_bib36","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbrc.2012.07.086","article-title":"Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation","volume":"425","author":"Shiraishi","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2023.115345_bib37","first-page":"3573","article-title":"Glucagon-like peptide-1 modulates RAW264.7 macrophage polarization by interfering with the JNK\/STAT3 signaling pathway","volume":"17","author":"Wan","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.biopha.2023.115345_bib38","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00125-013-3145-0","article-title":"Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus","volume":"57","author":"Hogan","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2023.115345_bib39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1053\/jhep.2003.50316","article-title":"Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E","volume":"38","author":"Kugelmas","year":"2003","journal-title":"Hepatol. (Baltim., Md. )"},{"key":"10.1016\/j.biopha.2023.115345_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166048","article-title":"Pro-Inflammatory Cytokines but Not Endotoxin-Related Parameters Associate with Disease Severity in Patients with NAFLD","volume":"11","author":"du Plessis","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.biopha.2023.115345_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144801","article-title":"Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2","volume":"131","author":"Liu","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2023.115345_bib42","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.3389\/fimmu.2020.01802","article-title":"Chemokines in non-alcoholic fatty liver disease: a systematic review and network meta-analysis","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2023.115345_bib43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.clnesp.2021.08.028","article-title":"High prevalence of hepatic steatosis and hepatic fibrosis in patients with type 2 diabetes mellitus","volume":"46","author":"Gupta","year":"2021","journal-title":"Clin. Nutr. ESPEN"},{"key":"10.1016\/j.biopha.2023.115345_bib44","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002159","article-title":"Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease","volume":"94","author":"Yu","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.biopha.2023.115345_bib45","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1111\/jgh.14734","article-title":"Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease","volume":"34","author":"Tada","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2023.115345_bib46","article-title":"Risk of liver fibrosis in patients with prediabetes and diabetes mellitus","volume":"17","author":"Park","year":"2022","journal-title":"PloS One"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223011368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223011368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:50:43Z","timestamp":1782370243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223011368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":46,"alternative-id":["S0753332223011368"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115345","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NF\u03baB signaling","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115345"}}